Repurposing tretinoin, a vitamin A derivative, against Chikungunya virus infection
Journal of Virology · 2026
DOI: 10.1128/jvi.00558-26 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Virology, 2026. Verfasst von Soumyajit Ghosh und 11 weiteren Autor:innen. Beteiligte Einrichtung: BRIC-Institute of Life Sciences (ILS), Bhubaneswar, Odisha, India. Hauptthemen laut MEDLINE: Tretinoin, Chikungunya virus, Antiviral Agents, Chikungunya Fever. Die Arbeit nennt 73 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Indian Council of Medical Research, Department of Biotechnology, Ministry of Science and Technology, India.
Abstract (Originalsprache)
Chikungunya virus (CHIKV) has reemerged as a global pathogen causing serious public health threat, particularly due to the absence of specific antivirals. Retinoids, vitamin A derivatives, have demonstrated antiviral potential against different viral infections, yet their efficacy against alphaviruses has never been investigated. In this study, tretinoin (TR), or all-trans retinoic acid (ATRA), was evaluated for its anti-CHIKV activity using in vitro , in vivo , and ex vivo models. TR abrogated CHIKV infection efficiently in Vero and C2C12 cells, with a marked reduction (>90%) in viral RNA, proteins, and progeny formation. The IC 50 of TR against CHIKV was estimated to be 20.05 µM and 19.71 µM in Vero and C2C12 cells, respectively. Additionally, TR showed remarkable virucidal activity and effective inhibition during entry, as well as in the early stages of post-CHIKV infection. Next, the global transcriptome profile demonstrated that the “signaling by retinoic acid” pathway was significantly enriched after CHIKV infection, and retinoic acid receptors (RARs), specifically RAR-β, are the key mediators for the anti-CHIKV effect of TR. Further, the drug alters phosphorylated mitogen-activated protein kinases (MAPKs), NF-κB, and proinflammatory cytokines during CHIKV infection in RAW 264.7 cells. Interestingly, TR protected C57BL/6 mice from CHIKV challenge by diminishing viral burden, leading to reduced clinical scores and better survival. Similar observations were also noticed in the ex vivo models of CHIKV-infected primary human skeletal muscle myoblasts (HSMMs). In conclusion, this work demonstrated the repurposing potential of TR against CHIKV infection for the first time, encouraging its clinical validation toward future therapeutics. IMPORTANCE Chikungunya virus (CHIKV) is an arbovirus causing Chikungunya fever (CHIKF), leading to debilitating arthralgia and myalgia. The unavailability of licensed antivirals against CHIKV encourages extensive research to find a therapeutic cure. Retinoids, the derivatives of vitamin A, have been repurposed as antiviral agents against a broad range of viruses; however, their potency against alphaviruses remains unexplored. Accordingly, tretinoin (TR), also known as all-trans retinoic acid (ATRA), was validated for anti-CHIKV efficacy in this investigation. Significant perturbations of CHIKV titer, RNA, and protein levels were observed in the presence of TR following infection, and its antiviral effect was mediated through RAR-β. Moreover, the anti-CHIKV potential of TR was evaluated in the mouse model and primary human skeletal muscle myoblasts, indicating strong preclinical efficacy. Finally, this is the first study to report the antiviral property of TR against CHIKV infection using in vitro , in vivo , and ex vivo approaches, suggesting its repurposing potential.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- BRIC-Institute of Life Sciences (ILS), Bhubaneswar, Odisha, India.
- Regional Centre for Biotechnology (RCB), Faridabad, Haryana, India.
- School of Biological Sciences, National Institute of Science Education and Research Bhubaneswar, Jatni, Odisha, India.
- Homi Bhabha National Institute, Mumbai, Maharashtra, India.
- National Institute of Allergy and Infectious Diseases (NIAID), Bethesda, Maryland, USA.
- Department of Neurosurgery, University of Michigan, Ann Arbor, Michigan, USA.
ORCID-Profile: Soumyajit Ghosh, Chandan Mahish, Archana Mahapatra, Tathagata Mukherjee, Pratima Kumari, Bijita Bhowmick, Saikat De, Udvas Ghorai, Rajshree Rajmohan Jena, Seema Pradhan, Subhasis Chattopadhyay, Soma Chattopadhyay
Förderung
- Indian Council of Medical Research
- Department of Biotechnology, Ministry of Science and Technology, India
Zitieren
APA
Ghosh, S., Mahish, C., Mahapatra, A., Mukherjee, T., Kumari, P., Bhowmick, B., De, S., Ghorai, U., Jena, R. R., Pradhan, S., Chattopadhyay, S., & Chattopadhyay, S. (2026). Repurposing tretinoin, a vitamin A derivative, against Chikungunya virus infection. Journal of Virology. https://doi.org/10.1128/jvi.00558-26
Vancouver
Ghosh S, Mahish C, Mahapatra A, Mukherjee T, Kumari P, Bhowmick B, et al. Repurposing tretinoin, a vitamin A derivative, against Chikungunya virus infection. Journal of Virology. 2026. doi:10.1128/jvi.00558-26
BibTeX
@article{Ghosh2026,
author = {Ghosh, Soumyajit and Mahish, Chandan and Mahapatra, Archana and Mukherjee, Tathagata and Kumari, Pratima and Bhowmick, Bijita and De, Saikat and Ghorai, Udvas and Jena, Rajshree Rajmohan and Pradhan, Seema and Chattopadhyay, Subhasis and Chattopadhyay, Soma},
title = {Repurposing tretinoin, a vitamin A derivative, against Chikungunya virus infection},
journal = {Journal of Virology},
year = {2026},
doi = {10.1128/jvi.00558-26}
}
EUVIMED